300 related articles for article (PubMed ID: 21626061)
1. PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH).
Gupta V; Davis M; Hope-Weeks LJ; Ahsan F
Pharm Res; 2011 Jul; 28(7):1733-49. PubMed ID: 21626061
[TBL] [Abstract][Full Text] [Related]
2. Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator.
Gupta V; Ahsan F
Int J Pharm; 2011 Jul; 413(1-2):51-62. PubMed ID: 21530623
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension.
Gupta V; Rawat A; Ahsan F
J Pharm Sci; 2010 Apr; 99(4):1774-89. PubMed ID: 19894275
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes.
Koushik K; Dhanda DS; Cheruvu NP; Kompella UB
Pharm Res; 2004 Jul; 21(7):1119-26. PubMed ID: 15290850
[TBL] [Abstract][Full Text] [Related]
5. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.
Ungaro F; d'Emmanuele di Villa Bianca R; Giovino C; Miro A; Sorrentino R; Quaglia F; La Rotonda MI
J Control Release; 2009 Apr; 135(1):25-34. PubMed ID: 19154761
[TBL] [Abstract][Full Text] [Related]
6. Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.
Gupta V; Gupta N; Shaik IH; Mehvar R; Nozik-Grayck E; McMurtry IF; Oka M; Komatsu M; Ahsan F
Mol Pharm; 2013 May; 10(5):1655-67. PubMed ID: 23485062
[TBL] [Abstract][Full Text] [Related]
7. How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin/hydroxypropyl-beta-cyclodextrin system.
De Rosa G; Larobina D; Immacolata La Rotonda M; Musto P; Quaglia F; Ungaro F
J Control Release; 2005 Jan; 102(1):71-83. PubMed ID: 15653135
[TBL] [Abstract][Full Text] [Related]
8. Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).
Rashid J; Patel B; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
J Control Release; 2017 Mar; 250():96-106. PubMed ID: 28185800
[TBL] [Abstract][Full Text] [Related]
9. Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery.
Vega E; Egea MA; Calpena AC; Espina M; García ML
Int J Nanomedicine; 2012; 7():1357-71. PubMed ID: 22457594
[TBL] [Abstract][Full Text] [Related]
10. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation.
Rawat A; Majumder QH; Ahsan F
J Control Release; 2008 Jun; 128(3):224-32. PubMed ID: 18471921
[TBL] [Abstract][Full Text] [Related]
11. Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray-drying.
Quaglia F; De Rosa G; Granata E; Ungaro F; Fattal E; Immacolata La Rotonda M
J Control Release; 2003 Jan; 86(2-3):267-78. PubMed ID: 12526823
[TBL] [Abstract][Full Text] [Related]
12. Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles.
Kadari A; Gudem S; Kulhari H; Bhandi MM; Borkar RM; Kolapalli VR; Sistla R
Drug Deliv; 2017 Nov; 24(1):224-232. PubMed ID: 28156161
[TBL] [Abstract][Full Text] [Related]
13. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs.
Ungaro F; De Rosa G; Miro A; Quaglia F; La Rotonda MI
Eur J Pharm Sci; 2006 Aug; 28(5):423-32. PubMed ID: 16806857
[TBL] [Abstract][Full Text] [Related]
14. Design and development of a novel controlled release PLGA alginate-pectinate polyspheric drug delivery system.
Sweet JL; Pillay V; Choonara YE
Drug Deliv; 2007 Jul; 14(5):309-18. PubMed ID: 17613019
[TBL] [Abstract][Full Text] [Related]
15. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses.
Thomas C; Gupta V; Ahsan F
Int J Pharm; 2009 Sep; 379(1):41-50. PubMed ID: 19524654
[TBL] [Abstract][Full Text] [Related]
16. Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lactic-co-glycolic acid) degradation during in vitro testing.
Witschi C; Doelker E
J Control Release; 1998 Feb; 51(2-3):327-41. PubMed ID: 9685930
[TBL] [Abstract][Full Text] [Related]
17. Development of highly porous large PLGA microparticles for pulmonary drug delivery.
Yang Y; Bajaj N; Xu P; Ohn K; Tsifansky MD; Yeo Y
Biomaterials; 2009 Apr; 30(10):1947-53. PubMed ID: 19135245
[TBL] [Abstract][Full Text] [Related]
18. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.
Kim H; Lee J; Kim TH; Lee ES; Oh KT; Lee DH; Park ES; Bae YH; Lee KC; Youn YS
Pharm Res; 2011 Aug; 28(8):2008-19. PubMed ID: 21472489
[TBL] [Abstract][Full Text] [Related]
19. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations.
Devrim B; Bozkır A; Canefe K
Drug Dev Ind Pharm; 2011 Nov; 37(11):1376-86. PubMed ID: 21548727
[TBL] [Abstract][Full Text] [Related]
20. Preparation and in vitro/in vivo evaluation of PLGA microspheres containing norquetiapine for long-acting injection.
Park CW; Lee HJ; Oh DW; Kang JH; Han CS; Kim DW
Drug Des Devel Ther; 2018; 12():711-719. PubMed ID: 29670329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
